ArticleEcancermedicalscience2025
Predictors of acute upper GI toxicity and its correlation with dosimetric analysis in patients receiving adjuvant radiation therapy for breast cancer.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most common malignancy in women worldwide, with significant geographic variation in incidence. Adjuvant radiotherapy (RT) improves outcomes but can cause underrecognised toxicities such as radiation-induced nausea, vomiting (RINV) and esophagitis. This study aims to correlate RINV and esophagitis with organ-at-risk (OAR) dose constraints and clinical factors. Materials and method: This prospective observational study analysed upper gastrointestinal (GI) toxicity in breast cancer patients receiving adjuvant RT. Patient demographics, clinical characteristics and dose-volume parameters for the stomach and esophagus were recorded. Statistical analyses identified predictors of RINV and esophagitis using univariate and multivariate models. Significant correlations were reported with a Results: The study included 110 female breast cancer patients (mean age 51 years), with volumetric modulated arc therapy (VMAT) as the predominant radiation technique and moderate hypofractionation (42.56 Gy/16 fractions) as the most prescribed regimen. Acute upper GI toxicity was observed in 60.9% of patients, with 3.6% experiencing Grade 3 toxicity. Higher stomach dose exposure (D10, D30 and D60cc) significantly correlated with increased toxicity ( Conclusion: Radiation technique, dose-volume parameters and breathing strategy significantly influence acute upper GI toxicity and dysphagia in breast cancer RT. DIBH reduces GI toxicity risk, while higher stomach and esophageal doses correlate with increased toxicity. Incorporating the stomach as an OAR and optimising treatment planning can enhance tolerability and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.